Affiliation: University of Wollongong
- Repaglinide in combination therapyR Moses
University of Wollongong, New South Wales, Australia
Diabetes Nutr Metab 15:33-8. 2002..In conclusion, repaglinide has additive, and often synergistic, effects on glycaemic control when given in combination regimens and should be a valuable option in the management of patients with T2DM...
- Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetesR Moses
Department of Endocrinology, Illawarra Regional Hospital, Wollongong, Australia
Diabetes Care 22:119-24. 1999..To compare the effect of repaglinide in combination with metformin with monotherapy of each drug on glycemic control in patients with type 2 diabetes...
- Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trialG R Dagenais
Laval University Heart and Lung Institute, 2725 Chemin Ste Foy, Quebec, Quebec City, Canada
Diabetes Care 31:1007-14. 2008..We determined the effects of ramipril and rosiglitazone on combined and individual CVD and renal outcomes in people with IGT and/or IFG in the Diabetes REduction Assessment With ramipril and rosiglitazone Medication (DREAM) trial...
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetesAnushka Patel
N Engl J Med 358:2560-72. 2008..5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy. (ClinicalTrials.gov number, NCT00145925.)..